ICALZISS 340mmol / l solution for infusion medication leaflet

B05XA07 calcium chloride • Blood and blood forming organs | I.v. solution additives | Electrolyte solutions

Calcii chloridum is a medication used for the treatment of acute hypocalcemia, hyperkalemia, hypermagnesemia, and calcium channel blocker overdose. It provides calcium, an essential mineral for the normal functioning of the nervous, muscular, and cardiovascular systems, as well as for blood coagulation and bone health.

The medication is administered intravenously, usually as a slow injection or infusion, as directed by a doctor. The dosage is adjusted based on the severity of the condition and the patient's response to treatment.

Common side effects include a sensation of warmth, metallic taste, nausea, and irritation at the injection site. In rare cases, more severe adverse effects such as cardiac arrhythmias, hypercalcemia, or tissue necrosis in cases of extravascular administration may occur.

Calcii chloridum is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions. Additionally, administration should be performed by qualified medical personnel to minimize the risks associated with this medication.

General data about ICALZISS 340mmol / l

Substance: calcium chloride

Date of last drug list: 01-06-2025

Commercial code: W71072001

Concentration: 340mmol / l

Pharmaceutical form: solution for infusion

Quantity: 20

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: BIEFFE MEDITAL S.P.A. - SPANIA

Holder: VANTIVE BELGIUM SRL - BELGIA

Number: 15975/2025/01

Shelf life: 1 year-after packing for marketing;Dupa prima deschidere a pungii-72 h

Pharmaceutical forms available for calcium chloride

Concentrations available for calcium chloride

100mmol/l, 12.2%, 340mmol/l